Cixutumumab

Cixutumumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IGF-1 receptor
Identifiers
CAS Number	947687-12-9 N
ATC code	none
UNII	2285XW22DR Y
KEGG	D09328 Y
Chemical data
Formula	C6500H10052N1724O2036S44
Molecular mass	146.3 kg/mol
NY (what is this?)  (verify)

Cixutumumab is a monoclonal antibody for the treatment of solid tumors.

This drug was developed by ImClone Systems Inc. under the name IMC-A12.

It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.